Cargando…

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab

Follicular lymphoma is the most common indolent non-Hodgkin’s lymphoma, and because of the incurable nature of this disorder, new therapies are constantly needed. The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and manageable toxicities for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopedote, Paolo, Shadman, Mazyar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024536/
https://www.ncbi.nlm.nih.gov/pubmed/36941881
http://dx.doi.org/10.2147/CMAR.S381493
_version_ 1784909128525676544
author Lopedote, Paolo
Shadman, Mazyar
author_facet Lopedote, Paolo
Shadman, Mazyar
author_sort Lopedote, Paolo
collection PubMed
description Follicular lymphoma is the most common indolent non-Hodgkin’s lymphoma, and because of the incurable nature of this disorder, new therapies are constantly needed. The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and manageable toxicities for patients with relapsed or refractory follicular lymphoma. Namely, as opposed to cellular immunotherapy options, this agent has the potential of being effective in patients with unfavorable features with a tolerable rate and severity of cytokine release syndrome, immune effector cell-associated neurotoxicity, and infectious complications. Given the recent withdrawal from the market of PI3K inhibitors and the practical challenges in utilizing with chimeric antigen receptor T-cells (CAR-T) for some patients, mosunetuzumab represents a “breath of fresh air” for both patients and hemato-oncologists. More data are required to better define the real potential of this molecule, either alone or in combination with other agents, including antibody drug conjugates, immunomodulators, and checkpoint inhibitors. Future studies will also shed light on the efficacy of mosunetuzumab compared with CAR-T, in well-designed registries or ideally in randomized controlled trials.
format Online
Article
Text
id pubmed-10024536
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-100245362023-03-19 Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab Lopedote, Paolo Shadman, Mazyar Cancer Manag Res Review Follicular lymphoma is the most common indolent non-Hodgkin’s lymphoma, and because of the incurable nature of this disorder, new therapies are constantly needed. The recently approved T-cell-dependent bispecific antibody mosunetuzumab showed promising results and manageable toxicities for patients with relapsed or refractory follicular lymphoma. Namely, as opposed to cellular immunotherapy options, this agent has the potential of being effective in patients with unfavorable features with a tolerable rate and severity of cytokine release syndrome, immune effector cell-associated neurotoxicity, and infectious complications. Given the recent withdrawal from the market of PI3K inhibitors and the practical challenges in utilizing with chimeric antigen receptor T-cells (CAR-T) for some patients, mosunetuzumab represents a “breath of fresh air” for both patients and hemato-oncologists. More data are required to better define the real potential of this molecule, either alone or in combination with other agents, including antibody drug conjugates, immunomodulators, and checkpoint inhibitors. Future studies will also shed light on the efficacy of mosunetuzumab compared with CAR-T, in well-designed registries or ideally in randomized controlled trials. Dove 2023-03-14 /pmc/articles/PMC10024536/ /pubmed/36941881 http://dx.doi.org/10.2147/CMAR.S381493 Text en © 2023 Lopedote and Shadman. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Lopedote, Paolo
Shadman, Mazyar
Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
title Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
title_full Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
title_fullStr Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
title_full_unstemmed Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
title_short Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
title_sort targeted treatment of relapsed or refractory follicular lymphoma: focus on the therapeutic potential of mosunetuzumab
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10024536/
https://www.ncbi.nlm.nih.gov/pubmed/36941881
http://dx.doi.org/10.2147/CMAR.S381493
work_keys_str_mv AT lopedotepaolo targetedtreatmentofrelapsedorrefractoryfollicularlymphomafocusonthetherapeuticpotentialofmosunetuzumab
AT shadmanmazyar targetedtreatmentofrelapsedorrefractoryfollicularlymphomafocusonthetherapeuticpotentialofmosunetuzumab